Johns Hopkins ABX Guide
Tixagevimab and Cilgavimab
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
Due to the emergence of Omicron subvariants that evade the effect of this drug’s two monoclonal antibodies, FDA withdrew the EUA (1/26/23).
The FDA issued an Emergency Use Authorization (EUA) permitting the emergency use of tixagevimab/cilgavimab for pre-exposure (PrEP) of COVID-19 in adults and pediatric patients (≥12 years of age and at least 40kg) who are not currently infected with SARS-CoV-2, have not had recent exposure to SARS-CoV-2.
AND
- Have moderate to severe immune-compromised status due to a medical condition or immunosuppressive medications/treatment and may not mount an adequate immune response from COVID-19 vaccination
OR
- For whom vaccination with any available COVID-19 vaccine, according to the approved/authorized schedule, is not recommended due to a history of severe adverse reaction (e.g. severe allergic reaction) to a COVID-19 vaccine and/or vaccine component
Tixagevimab/cilgavimab is NOT indicated for:
- The treatment of COVID-19 disease
- Post-exposure (PEP) of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2
PrEP is not a substitute for vaccination in individuals for whom vaccination is recommended. For individuals who have been vaccinated, tixagevimab/cilgavimab should be administered 2 weeks after vaccine administration.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
Due to the emergence of Omicron subvariants that evade the effect of this drug’s two monoclonal antibodies, FDA withdrew the EUA (1/26/23).
The FDA issued an Emergency Use Authorization (EUA) permitting the emergency use of tixagevimab/cilgavimab for pre-exposure (PrEP) of COVID-19 in adults and pediatric patients (≥12 years of age and at least 40kg) who are not currently infected with SARS-CoV-2, have not had recent exposure to SARS-CoV-2.
AND
- Have moderate to severe immune-compromised status due to a medical condition or immunosuppressive medications/treatment and may not mount an adequate immune response from COVID-19 vaccination
OR
- For whom vaccination with any available COVID-19 vaccine, according to the approved/authorized schedule, is not recommended due to a history of severe adverse reaction (e.g. severe allergic reaction) to a COVID-19 vaccine and/or vaccine component
Tixagevimab/cilgavimab is NOT indicated for:
- The treatment of COVID-19 disease
- Post-exposure (PEP) of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2
PrEP is not a substitute for vaccination in individuals for whom vaccination is recommended. For individuals who have been vaccinated, tixagevimab/cilgavimab should be administered 2 weeks after vaccine administration.
There's more to see -- the rest of this topic is available only to subscribers.
